Trial
NCT06466187
A Study of SGN-MesoC2 in Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Collaborators
—
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
PF-08052666
Why stopped
The trial was terminated for strategic reasons. The decision was not based on any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24